Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 1/2011

01-05-2011 | Treatment

Migraine with aura: conventional and non-conventional treatments

Authors: Giovanni D’Andrea, Davide Colavito, Maurizio Dalle Carbonare, Alberta Leon

Published in: Neurological Sciences | Special Issue 1/2011

Login to get access

Abstract

Migraine with aura (MwA) is a primary headache that affects up 30% of migraine patients. Although the frequency of MwA attacks is usually low and the majority of migraine sufferers do not need prophylactic treatment(s), same particular patients do. This occurs when the neurological symptoms, that characterize the auras, determine anxiety to the migraine sufferers and when the frequency of MwA attacks is or becomes high. In this study, we review the few therapeutic conventional options specifically devoted to cure MwA attacks present in the literature together with those, recent, non-conventional.
Literature
1.
Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of migraine in a population based cohort: the GEM study. Neurology 53:537–542PubMed
2.
Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(suppl 7):1–96
3.
Stewart WF, Schechter A, Lipton RB (1994) Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44(suppl 4):24–39
4.
Leao AAP (1944) Spreading depression of activity of cerebral cortex. J Neurophysiol 7:279–390
5.
Olesen J, Larsen B, Luritzen M (1981) Focal hyperemia followed by spreading olegimia an impaired activation of rCBF in classic migraine. Ann Neurol 14:344–352CrossRef
6.
D’Andrea G, Leon A (2010) Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurolo Sci 31(Suppl 1):S1–S7CrossRef
7.
Aurora KS, Cao Y, Bowyer SM, Welch KMA (1999) The occipital cortex is hyperexcitable inmigraine: experimental evidences. Headache 39(7):469–476PubMedCrossRef
8.
Lang E, Kaltenhauser M, Neundorfer B, Seidler S (2004) Hyperexcitability of the primary somatosensory cortex in migraine-a magnetoencephlographic study. Brain 127:2459–2469PubMedCrossRef
9.
Welch KMA (1987) Migraine. A biobehavioral disorder. Arch Neurol 44:1899–1987
10.
Mangano RM, Schwarcz R (1981) The human platelet as a model for the glutamatergic neuron: platelt uptake of l-glutamate. J Neurochem 36(3):1067–1076PubMedCrossRef
11.
D’Andrea G, Cananzi AR, Joseph R, Morra M, Zamberlan F, Ferro Milone F, Grunfeld S, Welch KMA (1991) Platelet glycine glutamate and aspartate in primary headache glutamate and aspartate in primary headache. Cephalalgia 11:197–200PubMedCrossRef
12.
Cananzi AR, D’Andrea G, Perini F, zamberlan F, Welch KMA (1995) Plasma and platelet levels of glutamate and glutamine in migraine with and without aura. Cephalagia 15:132–135CrossRef
13.
Prescot A, Becerra L, Pendse G, tully S, Burnstein R et al (2009) Excitatory neurotransmitters in brain regions in the interictal migraine patients. Mol Pain 5:34PubMedCrossRef
14.
D’Andrea G, Toldo M, Cortelazzo S, Ferro Milone F (1982) Platelet activity in migraine. Hedache 22:207–212CrossRef
15.
D’Andrea G, Hasselmark L, Alecci M, Cananzi AR, Perini F, Welch KMA (1994) Platelet secretion from dense and α-granules in vitro in migraine with and without aura. J Neurol Neurosurg Psychiatry 57(5):557–561PubMedCrossRef
16.
Joseph R, Welch KMA, D’Andrea G, Levine SR (1987) Sensitivity to PAF is increased inmigraine patients. Thromb Haemost 57:125PubMed
17.
Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, Capocchi G, Gallai V (2004) Platelet activating factor (PAF) in internal jugualr venous blood of migraine without aura assessed during migraine attacks. Cephalagia 24:623–630CrossRef
18.
D’Andrea G, Cananzi AR, Perini F, Hasselmark L (1995) Platelet models and their possible usefulness in study of migraine pathogenesis. Cephalalgia 15:265–271PubMedCrossRef
19.
Anzola GP, Magoni M, Guindani M et al (1999) Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 52:1622–1625PubMed
20.
Carrerj S, Narbone MC, Zito C, serra S, Coglitore S, Pugliatti P, Luz Arrigo F, Oreto G (2003) Prevalence of atrial septum aneurysm in patients with migraine echocardiographic study. Headache 43((7):725–728CrossRef
21.
D’Andrea G, Bonavita V, Rigamonti A, Bussone G (2003) Treatment of migraine with aura: comments and prospectives. Neurol Sci 23:271–278PubMedCrossRef
22.
Montagna P, Sacquegna T, Cortelli P, Lugaresi E (1989) Migraine as defect of brain oxidative metabolism: a hypothesis. J Neurol 236:124–125PubMedCrossRef
23.
Jensen K, Tfelt Hansen P, Lauritzen M, Olesen J (1985) Clinical trial of nimodipine for single attacks of classical migraine. Cephalalgia 5:125–131PubMedCrossRef
24.
Goldner JA, Lewitt LP (1987) Treatment of complicated migraine with sublingual nifedipine. Headache 27:484–486PubMedCrossRef
25.
Banerjee M, Findley LJ (1992) Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 12:39–44PubMedCrossRef
26.
Bates D, Ashford E, Dowson R, Ensink FBM, Gilhus NE, Olesen J, Pilgrim AJ, Shvelin P (1994) Sumatriptan Aura Study Group. subcutaneous sumatriptan during the migraine aura. Neurology 44:1587–1592PubMed
27.
Hachinsky V, Norris JW, Edmeads J, Cooper PW (1978) Ergotamine and cerebral blood flow. Stroke 9:594–596
28.
Sanches del Rio M, Bakker D, O Wu et al (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19(8):701–707CrossRef
29.
Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogozo JM (1984) Reversible cerebral arteriopathy associated with the administration of ergot derivatives. Cephalalgia 4:171–178PubMedCrossRef
30.
Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139–141PubMed
31.
Rozen DT (2000) Treatment of prolonged migrainous aura with intravenous furosemide. Neurology 55:732–733PubMed
32.
Haan J, Sluis P, Sluis LH, Ferrari MD (2000) Acetazolamide treatment for migraine aura status. Neurology 55:1588–1589PubMed
33.
Cologno D, Torelli P, Cademartiri C, Manzoni GC (2000) A prospective study of migraine with aura attacks in a headache clinic population. Cephalalgia 20(10):925–930PubMedCrossRef
34.
Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Nyagaard Kristensen T, de Fine Olivarius B (1983) Prophylactic treatment of classical and non classical migraine with metoprolol a comparison with placebo. Cephalalgia 3:207–212PubMedCrossRef
35.
Kangasniemi P, Andersen AR, Andresson PG, Gilhus NE, Hedman C, Hultren M, Vilming S, Olesen J (1987) Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 7(4):231–238PubMedCrossRef
36.
Kangasniemi P, Hedman C (1984) Metoprolol and propranolol in the prophylactic treatment of classical and common migraine: a double-blind study. Cephalalgia 4:91–96PubMedCrossRef
37.
Hedman C, Andressen AR, Andresson PG, Gilhus NE, Kangasniemi P, Olsson JE, Strandman E, Nestvold K, Olesen J (1988) Symptoms of classic migraine attacks: modifications brought about by metoprolol. Cephalalgia 8:279–284PubMedCrossRef
38.
Mentenopoulos G, Manafi TH, Logothetis J, Bostantzopoulou S (1985) Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 5(Suppl 2):134–140
39.
D’Andrea G, Nordera GP (2006) Allais G Treatment of aura: solving the puzzle Neurol Sci 27(Suppl 2):S96–S99
40.
D’Andrea G, Granella F, Cadaldini M, Manzoni GC (1999) Effectiveness of lamotrigine in the prophylaxis. Cephalalgia 19:64–66PubMedCrossRef
41.
Lampl C, Buzath A, Klinger D, Neumann K (1999) Lamotrigine in the prophylactic treatment of migraine with aura: a pilot study. Cephalalgia 19:58–63PubMedCrossRef
42.
Chen WT, Fuh JL, Lu SR, Wang SJ (2001) Persistent migraineous visual phenomena might be responsive to lamotrigine. Headache 41:823–825PubMedCrossRef
43.
D’Andrea G, Granella F, Verdelli F (2002) Migraine with aura triggered by orgasm. Cephalalgia 22(6):485–486PubMedCrossRef
44.
Pascual J, Caminero AB, Mateos V, Roig C, Leira R, Garcia-Monco C, Lainez MJ (2004) Preventing disturbing migraine with aura with lamotrigine: an open pilot study. Headache 44:1024–1028PubMedCrossRef
45.
Lampl C, Katsarava Z, Diener HC, Limmroth V (2006) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76:1730–1732CrossRef
46.
Steiner TJ, Findley LJ, Yeun AWC (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalagia 17:109–112CrossRef
47.
White HS, Brown Sd, Woodhead JH, Skeen GA, Wolf HH (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167–179PubMedCrossRef
48.
Cutrer FM (2001) Antiepileptic drugs: how they work in headache. Headache 41(Suppl 1):3–10CrossRef
49.
Lampl C, Bonelli S, Ramsmayr G (2004) Efficacy of topiramate in migraine with aura prophylaxis: preliminary results of 12 patients. Headache 44:174–177PubMedCrossRef
50.
Modesti PA, Colella A, Gensini G, Neri Serneri G (1989) Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 169(1):85–93PubMedCrossRef
51.
Allais G, D’Andrea G, Airola G, De Lorenzo C, Mana O, Benedetto C (2004) Picotamide in Migraine with aura prevention: a pilot study. Neurol Sci 25(Suppl 3):S267–S269PubMedCrossRef
52.
Wang SJ, Chen HH (2005) Ginkgolide b, a constituent of Ginkgo Biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminal. Eur J Pharmacol 514:141–149PubMed
53.
Kuribara K, Wardlaw AJ, Moqbel R, Kay AB (1989) Inhibition of platelet-activating factor (PAF) banding to human eosinophils and neutrophils by specific Ginkgolide-derived PAF antagonist BN52021. J Allergy Clin Immunol 83:83–90CrossRef
54.
Teather LA, Afonso VM, Wurtman RJ (2006) Inhibition of platelet-activating factor receptors in hippocampal plasma membranes attenuates the inflammatory nociceptive response in rats. Brain Res 1097(1):230–233PubMedCrossRef
55.
Xia SH, Fang DC (2007) Pharmacological action and mechanism of ginlgolide. Clin Med J 120(10):922–928
56.
Joseph R, Welch KM, D’Andrea G, Levine SR (1987) Sensitivity to PAF is increased inmigraine patients. Thromb Haemost 57(1):125PubMed
57.
D’Andrea G, Hasselmak L, Alecci M, Cananzi AR, Perini F, Welch KMA (1994) Platelet secretion from dense and α-granules in vitro in migraine with and without aura. J Neurosurg Psychiatry 57(5):557–561CrossRef
58.
Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, Capecchi G, Gallai V (2004) Platelet-activating factor (PAF) in internal jugular venous blood of migraine with and without Aura patients assessed during migraine attacks. Cephalalgia 24:623–630PubMedCrossRef
59.
Perini F, D’Andrea G, Galloni E et al (2005) Plasma cytochine levels in migraineurs and controls. Headache 45:926–931PubMedCrossRef
60.
Yoshikawa T, Nalto Y, Kondo M (1999) Gingko biloba leaf extract: review of biological action and clinical applications. Antioxid Redox Signal 1(4):469–480PubMedCrossRef
61.
Welch KM, Nagesh V, Aurora SK et al (2001) Periacquetuctal gay matter disfunction in migraine: cause or the burden of illness? Headache 7:629–637CrossRef
62.
Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC (2011) Gingkolide b and bilolabide block the pore of the 5-HT3 receptor at a location that overlap the picrotoxin binding site. Neuropharmacology 60(2–3):488–495
63.
Faris LP, Eckert DE, Kim Suck-Von, Meller HW, Pardo VJ, Goodale LR, Hartman KB (2006) Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disord 92:79–90PubMedCrossRef
64.
The International Classification of Headache Disorders (2004) 2nd edn. Cephalalgia 24(suppl-1):1–160
65.
D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Peretta V, Benedetto C (2009) Efficacy of Ginkolide b in the Prophylaxis of migraine with aura. Neurol Sci 30(Suppl 1):S121–S124PubMedCrossRef
66.
Evers S, Afra J, Frese A, Goasdsby J, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur J Neurol 16:968–998PubMedCrossRef
Metadata
Title
Migraine with aura: conventional and non-conventional treatments
Authors
Giovanni D’Andrea
Davide Colavito
Maurizio Dalle Carbonare
Alberta Leon
Publication date
01-05-2011
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2011
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-011-0529-0

Other articles of this Special Issue 1/2011

Neurological Sciences 1/2011 Go to the issue

Migraine Pathophysiology

Female reproductive steroids and neuronal excitability

Invited Lecture

Pain as an evolutionary necessity

Brief Communication

Polytherapy for the prophylaxis of chronic migraine: an Italian survey

Invited Lecture

New frontiers in headache therapy

Migraine Pathophysiology

The contribution of fMRI to elucidate the pathophysiology of primary headaches

Invited Lecture

New disposition for pain therapy in Italy, center for headache should be integrated in the network